Suppr超能文献

口服2'-脱氧-5-氟-5'-尿苷酸十四烷基酯后5-氟-2'-脱氧尿苷酸的抗肿瘤作用及肿瘤水平

Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.

作者信息

Nakajima Y, Iigo M, Hoshi A

机构信息

National Cancer Center Research Institute, Tokyo, Japan.

出版信息

Anticancer Drugs. 1992 Jun;3(3):289-92. doi: 10.1097/00001813-199206000-00013.

Abstract

The antitumor effect and tumor levels of 5-fluoro-2'-deoxyuridylate (FdUMP) following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate (TT-62) were compared with those attained following intravenous (i.v.) or intraperitoneal (i.p.) administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) in BDF1 mice bearing murine mammary adenocarcinoma 755 and athymic mice bearing the transplantable human colon adenocarcinoma LS174T. Oral administration of TT-62 showed a stronger antitumor effect against adenocarcinoma 755 than FUdR. The maximum effect of TT-62 was similar to that of 5-FU. However, TT-62 and FUdR treatments were more effective than i.v. administration of 5-FU against LS174T. Thus, oral administration of TT-62 showed marked antitumor activity in both tumor systems. The maximum tolerated dose of FUdR resulted in a much higher level of free FdUMP in the LS174T tumor than that obtained with 5-FU. After oral administration of TT-62 the levels of FdUMP in the tumor were about 10 times those attained with 5-FU, but significantly lower than the levels obtained following i.v. administration of FUdR. With TT-62 the levels of FdUMP in the tumor reached their peak at 60 min following the administration and gradually decreased thereafter. However, FdUMP levels after administration of FUdR decreased rapidly. Three hours after the administration of TT-62 and for up to 24 h the FdUMP levels in the LS174T tumor were almost the same as after administration of FUdR, i.e. effective levels of FdUMP were maintained for a long time with TT-62.

摘要

在携带小鼠乳腺腺癌755的BDF1小鼠和携带可移植人结肠腺癌LS174T的无胸腺小鼠中,比较了口服十四烷基2'-脱氧-5-氟-5'-尿苷酸(TT-62)后5-氟-2'-脱氧尿苷酸(FdUMP)的抗肿瘤作用和肿瘤水平,以及静脉注射(i.v.)或腹腔注射(i.p.)5-氟尿嘧啶(5-FU)或5-氟-2'-脱氧尿苷(FUdR)后所达到的水平。口服TT-62对腺癌755显示出比FUdR更强的抗肿瘤作用。TT-62的最大作用与5-FU相似。然而,TT-62和FUdR治疗对LS174T比静脉注射5-FU更有效。因此,口服TT-62在两种肿瘤系统中均显示出显著的抗肿瘤活性。FUdR的最大耐受剂量导致LS174T肿瘤中游离FdUMP的水平比5-FU所获得的值高得多。口服TT-62后肿瘤中FdUMP的水平约为5-FU所达到水平的10倍,但明显低于静脉注射FUdR后所获得的水平。使用TT-62时,肿瘤中FdUMP的水平在给药后60分钟达到峰值,此后逐渐下降。然而,FUdR给药后FdUMP水平迅速下降。给予TT-62后3小时直至24小时,LS174T肿瘤中FdUMP的水平几乎与给予FUdR后相同,即TT-62能长时间维持FdUMP的有效水平。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验